Ranolazine: A Contemporary Review of its Use in the Treatment of Nonalcoholic Fatty Liver Disease

Abstract

Ranolazine, a synthetic crystalline compound with basic properties derivative sold under the trade name RANOZEAL, is an acceptedmedicine thatselectively prevents the ongoing chest pain or pressure felt when the heart does not get enough oxygen. In addition, ranolazine has valuable metabolic assetsand does not influence heart rate or blood stress. Ranolazine is presentlyauthorized in the United States, Europe, and India as a second agent in managing angina pectoris. Nonalcoholic fatty liver disease (NAFLD) is an increasing pandemic in India, but global in part due to obesity and insulin resistance leading to liver growth of triglycerides and free fatty acids. As a result, NAFLD patients are at increased risk of liver-associated and cardiac death, and NAFLD is quickly developing the primary symptom for liver replacement. Several risk components for NAFLD growth have been adopted, with most allowing some form of metabolic derangement or insulin resistance at the core of its pathophysiology. This studygives acompleteanalysis of the pharmacology, standards, andanalyzed uses of ranolazine.